Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2001 Sep;2(9):1273-8.

LY-293558. Eli Lilly & Co.

Author information

  • Departments of Anesthesiology and Pharmacology & Toxicology, Queen's University, Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada. gilroni@post.queensu.ca

Abstract

Lilly is developing the racemic compound LY-215490, a selective and competitive AMPA antagonist, as a potential treatment for cerebral infarction, cerebrovascular ischemia, epilepsy and as an analgesic [135089], [158980], [254029], [278691]. By January 2000, LY-293558 was undergoing phase II trials for pain [414000].

PMID:
11717815
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk